ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
다형성 교모세포종 시장 규모는 향후 수년간 강력한 성장이 전망될 예정입니다. 예측 기간의 성장은 질병의 조기 진단, 연구 개발 활동의 급증에 기인한다고 생각됩니다. 이 기간에 예상되는 주요 동향에는 의료 기술의 진보, 화상 진단 기술의 향상, 맞춤형 의료의 확대, 진단을 위한 AI의 통합, 진행중의 기술적·과학적 발전이 포함됩니다.
뇌 장애의 증례 수 증가는 다형성 교모세포종 시장의 성장을 견인할 것으로 예측됩니다. 뇌 질환의 조사는 조기 발견, 혁신적인 치료, 환자 결과의 개선으로 이어지는 다형성 교모세포종(GBM)의 보다 나은 이해에 공헌합니다. 예를 들어, 2025년 2월 호주 치매협회(Dementia Australia)는 약 43만 3,300명의 호주인이 치매를 앓고 있으며 2054년에는 이 수가 81만 2,500명으로 증가할 것으로 예상한다고 보고했습니다. 또한 현재 약 2만 9,000명이 젊은 발병 치매를 앓고 있으며, 2054년에는 4만 1,000명으로 증가할 것으로 추정됩니다.
다형성 교모세포종 시장의 주요 기업은 침공성 뇌종양의 암멧 의료 요구에 대응하기 위해 CAR T 세포 요법과 같은 시장 개척에 주력하고 있습니다. T세포요법은 암세포를 보다 효과적으로 표적으로 파괴하기 위해 환자의 T세포를 변경하는 면역요법의 한 형태입니다. 2023년 6월, 호주에 본사를 둔 생명공학 회사인 키메릭 테라퓨틱스(Chimeric Therapeutics Limited)는 재발성 또는 진행성 다형성 교모세포종(GBM) 환자를 대상으로 CHM 1101(CLXT CAR T) 치료에 대한 IB 임상시험을 개시했습니다. 여러 센터에서 실시되는 이 임상시험은 치료의 안전성과 효능을 평가하는 동시에 최적의 임상 2상 용량을 결정하는 것을 목표로 합니다. 초기 임상 1a상 결과에서 질병의 안정성이 입증되었으며, 새로운 임상시험에서는 이러한 결과를 바탕으로 치료법 개발을 진전시키고자 합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 다형성 교모세포종 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 다형성 교모세포종 시장 : 성장률 분석
세계의 다형성 교모세포종 시장 실적 : 규모와 성장(2019-2024년)
세계의 다형성 교모세포종 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 다형성 교모세포종 전체 시장(TAM)
제6장 시장 세분화
세계의 다형성 교모세포종 시장 : 약제 클래스별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
화학요법제
테모졸로마이드
카르무스틴
로무스틴
기타
세계의 다형성 교모세포종 시장 : 진단 도구별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
자기 공명 영상(MRI)
컴퓨터 단층 촬영 스캔(CT 스캔)
생검
기타 진단 도구
세계의 다형성 교모세포종 시장 : 치료 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
수술
방사선 치료
화학 요법
면역 요법
종양 치료 분야 요법
기타 치료 유형
세계의 다형성 교모세포종 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원
암 연구 기관
외래수술센터(ASC)
기타
세계의 다형성 교모세포종 시장 : 화학요법제 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
알킬화제
백금 기반 제제
항대사제
세계의 다형성 교모세포종 시장 : 테모졸로미드 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
브랜드(테모다르)
일반 테모졸로미드
세계의 다형성 교모세포종 시장 : 카르무스틴 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
주사용 카르무스틴
카르무스틴 웨이퍼(글리아델)
세계의 다형성 교모세포종 시장 : 로무스틴 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
브랜드(글로스틴)
일반 로무스틴
세계의 다형성 교모세포종 시장 : 기타 약제 클래스 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
표적 치료
면역 치료
종양 치료 분야(TTF) 요법
제7장 지역별/국가별 분석
세계의 다형성 교모세포종 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 다형성 교모세포종 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
다형성 교모세포종 시장 : 경쟁 구도
다형성 교모세포종 시장 : 기업 프로파일
Pfizer Inc.
F. Hoffmann-La Roche Ltd.
AbbVie Inc.
Bristol Myers Squibb Company
AstraZeneca PLC
제31장 기타 주요 기업 및 혁신 기업
Novartis International AG
Eli Lilly and Company
Amgen Inc.
Merck KGaA
Teva Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd.
Zydus Pharmaceuticals(미국) Inc.
Accord Healthcare Inc.
Sumitomo Dainippon Pharma Oncology Inc.
Karyopharm Therapeutics Inc.
ITM Isotope Technologies Munich SE
Azurity Pharmaceuticals Inc.
Genenta Science SpA
Chimeric Therapeutics Limited
VBI Vaccines Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 전략
다형성 교모세포종 시장(2029년) : 새로운 기회를 제공하는 국가
다형성 교모세포종 시장(2029년) : 새로운 기회를 제공하는 부문
다형성 교모세포종 시장(2029년) : 성장 전략
시장 동향에 의한 전략
경쟁 전략
제36장 부록
KTH
영문 목차
영문목차
Glioblastoma multiforme (GBM) is a highly aggressive and fast-growing brain tumor that originates in the glial cells of the brain. It is the most lethal form of primary brain cancer, characterized by rapid proliferation and resistance to standard treatments.
The primary drug classes used for glioblastoma multiforme treatment include chemotherapy agents such as temozolomide, carmustine, lomustine, and others. These chemotherapy agents work by targeting and disrupting cancer cell division, helping to control tumor growth and improve survival, often in combination with other treatments. Diagnosis is performed using various tools, including magnetic resonance imaging (MRI), computed tomography (CT) scans, biopsies, and others. Treatment options include surgery, radiation therapy, chemotherapy, immunotherapy, tumor treating field therapy, and more. The drugs and treatments are utilized by various end-users, including hospitals, cancer research institutes, and ambulatory surgical centers.
The glioblastoma multiforme market research report is one of a series of new reports from The Business Research Company that provides glioblastoma multiforme market statistics, including the glioblastoma multiforme industry global market size, regional shares, competitors with the glioblastoma multiforme market share, detailed glioblastoma multiforme market segments, market trends, and opportunities, and any further data you may need to thrive in the glioblastoma multiforme industry. This glioblastoma multiforme market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The glioblastoma multiforme market size has grown strongly in recent years. It will grow from $2.50 billion in 2024 to $2.71 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth during the historic period was driven by the increasing incidence of glioblastoma multiforme, advancements in healthcare infrastructure, greater awareness, improved access to advanced therapies, and a growing aging population.
The glioblastoma multiforme market size is expected to see strong growth in the next few years. It will grow to $3.69 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The projected growth in the forecast period can be attributed to the rising cases of brain and other nervous system cancers, increased acceptance of surgical techniques, heightened awareness, early disease diagnosis, and a surge in research and development activities. Key trends expected in this period include advancements in medical technology, improvements in imaging techniques, the expansion of personalized medicine, the integration of AI for diagnosis, and ongoing technological and scientific developments.
The increasing number of brain disorder cases is expected to drive the growth of the glioblastoma multiforme market. Brain disorders affect the structure or function of the brain, leading to cognitive, emotional, or physical impairments. The rising prevalence of these conditions is attributed to factors such as aging populations, increased life expectancy, lifestyle changes, and advancements in diagnostic technology. Research into brain disorders contributes to a better understanding of glioblastoma multiforme (GBM), leading to improvements in early detection, innovative treatments, and enhanced patient outcomes. By studying neurological conditions, scientists can identify genetic and molecular factors that contribute to GBM development. For example, in February 2025, Dementia Australia reported that approximately 433,300 Australians are living with dementia, with this number projected to increase to 812,500 by 2054. Additionally, younger-onset dementia currently affects around 29,000 people, with estimates suggesting an increase to 41,000 by 2054. As brain disorder cases continue to rise, the glioblastoma multiforme market is expected to expand.
Leading companies in the glioblastoma multiforme market are focusing on developing advanced therapies, such as CAR T-cell therapies, to address the unmet medical needs of aggressive brain cancer. CAR T-cell therapy is a form of immunotherapy that modifies a patient's T-cells to target and destroy cancer cells more effectively. In June 2023, Chimeric Therapeutics Limited, an Australia-based biotech company, initiated a Phase IB clinical trial for CHM 1101 (CLXT CAR T) therapy in patients with recurrent or progressive glioblastoma multiforme (GBM). Conducted across multiple centers, the trial aims to assess the safety and efficacy of the therapy while determining the optimal Phase 2 dose. Early Phase 1a results demonstrated disease stability, and the new trial seeks to build on these findings to advance the therapy's development. The company intends to use the trial data to design a registration study and obtain regulatory feedback.
In January 2022, ITM Isotope Technologies Munich SE (ITM), a Germany-based radiopharmaceutical biotech company, partnered with Helmholtz Center Munich to enhance treatment options for glioblastoma multiforme. This collaboration focuses on advancing the clinical development of targeted radiopharmaceutical therapy, addressing a critical need for effective treatments for this aggressive cancer. Helmholtz Center Munich, a Germany-based research institution, specializes in the development of immunotherapy for glioblastoma treatment.
Major players in the glioblastoma multiforme market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Zydus Pharmaceuticals (USA) Inc., Accord Healthcare Inc., Sumitomo Dainippon Pharma Oncology Inc., Karyopharm Therapeutics Inc., ITM Isotope Technologies Munich SE, Azurity Pharmaceuticals Inc., Genenta Science S.p.A., Chimeric Therapeutics Limited, and VBI Vaccines Inc.
North America was the largest region in the glioblastoma multiforme market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in glioblastoma multiforme report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the glioblastoma multiforme market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The glioblastoma multiforme market consists of revenues earned by entities by providing services such as palliative care, psychosocial support, and rehabilitation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The glioblastoma multiforme market also includes sales of drugs, diagnostic tools, personalized medicine, and advanced drug delivery systems. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Glioblastoma Multiforme Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on glioblastoma multiforme market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for glioblastoma multiforme ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The glioblastoma multiforme market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Drug Class: Chemotherapy Agents; Temozolomide; Carmustine; Lomustine; Other Drug Classes
2) By Diagnostic Tools: Magnetic Resonance Imaging (MRI); Computed Tomography Scan (CT Scan); Biopsy; Other Diagnostic Tools
3) By Treatment Type: Surgery; Radiation Therapy; Chemotherapy; Immunotherapy; Tumor Treating Field Therapy; Other Treatment Types
4) By End-User: Hospitals; Cancer Research Institutes; Ambulatory Surgical Centers; Other End-Users
Subsegments:
1) By Chemotherapy Agents: Alkylating Agents; Platinum-Based Agents; Antimetabolites
2) By Temozolomide: Branded (Temodar); Generic Temozolomide
3) By Carmustine: Injectable Carmustine; Carmustine Wafers (Gliadel)
4) By Lomustine: Branded (Gleostine); Generic Lomustine
5) By Other Drug Classes: Targeted Therapy; Immunotherapy; Tumor-Treating Fields (TTF) Therapy
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Glioblastoma Multiforme Market Characteristics
3. Glioblastoma Multiforme Market Trends And Strategies
4. Glioblastoma Multiforme Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Glioblastoma Multiforme Growth Analysis And Strategic Analysis Framework
5.1. Global Glioblastoma Multiforme PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Glioblastoma Multiforme Market Growth Rate Analysis
5.4. Global Glioblastoma Multiforme Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Glioblastoma Multiforme Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Glioblastoma Multiforme Total Addressable Market (TAM)
6. Glioblastoma Multiforme Market Segmentation
6.1. Global Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chemotherapy Agents
Temozolomide
Carmustine
Lomustine
Other Drug Classes
6.2. Global Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Magnetic Resonance Imaging (MRI)
Computed Tomography Scan (CT Scan)
Biopsy
Other Diagnostic Tools
6.3. Global Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Surgery
Radiation Therapy
Chemotherapy
Immnuotherapy
Tumor Treating Field Therapy
Other Treatment Types
6.4. Global Glioblastoma Multiforme Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Cancer Research Institutes
Ambulatory Surgical Centres
Other End-Users
6.5. Global Glioblastoma Multiforme Market, Sub-Segmentation Of Chemotherapy Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Alkylating Agents
Platinum-Based Agents
Antimetabolites
6.6. Global Glioblastoma Multiforme Market, Sub-Segmentation Of Temozolomide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Branded (Temodar)
Generic Temozolomide
6.7. Global Glioblastoma Multiforme Market, Sub-Segmentation Of Carmustine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Injectable Carmustine
Carmustine Wafers (Gliadel)
6.8. Global Glioblastoma Multiforme Market, Sub-Segmentation Of Lomustine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Branded (Gleostine)
Generic Lomustine
6.9. Global Glioblastoma Multiforme Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Targeted Therapy
Immunotherapy
Tumor-Treating Fields (TTF) Therapy
7. Glioblastoma Multiforme Market Regional And Country Analysis
7.1. Global Glioblastoma Multiforme Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Glioblastoma Multiforme Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
